A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: The Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial

Gulizia, Michele Massimo; Mangiameli, S; Orazi, Serafino; Chiarandà, Giacomo; Piccione, Guglielmo; Giovanni, Nicolò Di; Colletti, Andrea; Pensabene, Orazio; Lisi, Francesco; Vasquez, Ludovico; Grammatico, Andrea; Boriani, Giuseppe

doi:10.1016/j.ahj.2007.08.033

Cited by 28 publications

(8 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, AADs are always required to control tachycardia‐related symptoms. The Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial had compared the efficacy and safety of amiodarone and Class IC AADs to treat AF in patients paced for SND; the authors found that only 40% of the amiodarone group and 28% of the Class IC AADs group were free from atrial tachyarrhythmias (episodes > 10 minutes) after 20 ± 9 months of follow‐up . In our study, only about one‐fifth of the patients in the PM group maintained sinus rhythm even though many patients were still on AADs at the end of follow‐up.…”

Section: Prolonged Sinus Pauses On Af Termination: Pace or Ablate?mentioning

confidence: 61%

Pacing or Ablation: Which Is Better for Paroxysmal Atrial Fibrillation‐Related Tachycardia‐Bradycardia Syndrome?

CHEN

Bai

Lin

et al. 2014

Pacing Clinical Electrophis

View full text Add to dashboard Cite

show abstract

Section: Prolonged Sinus Pauses On Af Termination: Pace or Ablate?mentioning

confidence: 61%

Pacing or Ablation: Which Is Better for Paroxysmal Atrial Fibrillation‐Related Tachycardia‐Bradycardia Syndrome?

CHEN

Bai

Lin

et al. 2014

Pacing Clinical Electrophis

View full text Add to dashboard Cite

show abstract

“…In our observational cohort, there were eight deaths during flecainide treatment, three of which were classified as SCD. Earlier studies revealed a total number of eight deaths in the AF population receiving flecainide (three because of noncardiac causes, four because of structural heart disease, and information was not available in the remaining case) [16–21]. In cases in which information was available, the occurrence of death ranged from 1 day to 2 months after flecainide treatment initiation.…”

Section: Discussionmentioning

confidence: 99%

The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events

Almroth

Andersson

Fengsrud

et al. 2011

Journal of Internal Medicine

View full text Add to dashboard Cite

show abstract

“…A few clinical studies have identified an overall increase in respiratory adverse effects [16,17]; however, none have specifically identified ALI/ARDS as being increased, either around the time of surgery [18,19] or with long-term use [20–23]. One clinical trial that did find a significant increase in ARDS was a nonblinded study of Belgian patients randomized to prophylactic placebo, verapamil, or amiodarone for the prevention of atrial fibrillation after lung cancer surgery [7].…”

Section: Discussionmentioning

confidence: 99%

Prehospital amiodarone may increase the incidence of acute respiratory distress syndrome among patients at risk

Karnatovskaia

Festić

Gajic

et al. 2012

Journal of Critical Care

View full text Add to dashboard Cite

Purpose Amiodarone has been implicated as a risk factor for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) when used in the hospital. This study aims to estimate whether prehospital amiodarone also increases the risk of ALI/ARDS. Materials Adult patients admitted to 22 centers with at least 1 risk factor for developing ALI were recruited. In a secondary analysis of this cohort, the prehospital use of amiodarone was documented on admission, and the patients followed for the primary outcome of ALI and secondary outcomes of ARDS, the need for invasive ventilation, and mortality. Dose/duration of amiodarone therapy was not available. Propensity matching was performed to account for imbalances in being assigned to amiodarone. The adjusted risk for ALI/ARDS was then estimated from a conditional logistic regression model of this propensity-matched set. Results Forty of 5584 patients were on amiodarone at the time of hospitalization; of those, 6 developed ALI, with 5 progressing to ARDS. In comparison, 371 patients not on amiodarone developed ALI, with 224 having ARDS. After propensity score matching, the prehospital use of amiodarone was not statistically associated with an increased risk for all ALI (odds ratio [OR], 1.8; 95% confidence interval [CI], 0.7–5.0; P = .25), invasive ventilation (OR, 1.9; 95% CI, 1.0–3.6; P = .059), or in-hospital mortality (OR, 1.2; 95% CI, 0.5–2.9; P = .75); but its use appeared to significantly increase the risk for ARDS (OR 3.8; 95% CI, 1.1–13.1; P = .036). Conclusions Prehospital use of amiodarone may independently increase the risk for ARDS in patients who have at least 1 predisposing condition for ALI.

show abstract

A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: The Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial

Cited by 28 publications

References 31 publications

Pacing or Ablation: Which Is Better for Paroxysmal Atrial Fibrillation‐Related Tachycardia‐Bradycardia Syndrome?

Pacing or Ablation: Which Is Better for Paroxysmal Atrial Fibrillation‐Related Tachycardia‐Bradycardia Syndrome?

The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events

Prehospital amiodarone may increase the incidence of acute respiratory distress syndrome among patients at risk

Contact Info

Product

Resources

About